Background Prediction of susceptibility to multiple sclerosis (MS) might have important clinical applications, either as part of a diagnostic algorithm or as a means to identify high-risk individuals for prospective studies. We investigated the usefulness of an aggregate measure of risk of MS that is based on genetic susceptibility loci. We also assessed the added eff ect of environmental risk factors that are associated with susceptibility for MS.
Introduction
Multiple sclerosis (MS) is an infl ammatory disease of the CNS. Several genetic and environmental susceptibility factors for MS have been identifi ed, including MHC and non-MHC loci.
1 Genome-wide association studies for Crohn's disease and type 1 diabetes mellitus 2, 3 have identifi ed more than 40 susceptibility alleles for each of these infl ammatory diseases; therefore, ongoing genomewide association studies for MS will probably identify many more susceptibility loci. Unlike HLA DRB1*1501, most of the genetic risk factors identifi ed so far have only a slight eff ect on susceptibility to MS (with odds ratios that range from 1·1 to 1·2); however, the risk alleles in these loci are common in people of European ancestry, with allele frequencies of 0·1-0·9. To date, there is little information on how this growing set of genetic susceptibility factors is aff ected by environmental risk factors such as infection with the Epstein-Barr virus (EBV), smoking, and serum vitamin D concentrations. 4 Although the early results from whole-genome association studies have not yet been used clinically, the translation of genetic and epidemiological risk factors to the clinic is needed. An important goal to understand the genetic basis of MS is to investigate the use of these allelic variants to predict disease risk, so that environmental changes or therapeutic interventions can be initiated before the infl ammatory demyelinating process starts. By combining family history with a quantitative measure of genetic risk, a screening method might eventually be implemented that could identify clinically silent evidence of disease among fi rst-degree relatives of patients with MS, who are 20-50 times more likely to develop MS than are the general population. 5 Although these individuals have a high risk of developing MS, the absolute risk is only 2-5%. 5 Therefore, in high-risk populations and in individuals who have had an initial episode of neurological defi cit with an unclear cause, novel clinical screening methods could be used to guide the selection of those individuals who will benefi t most from early imaging. The early detection of an infl ammatory demyelinating illness is useful because early treatment of individuals who have had one episode of infl ammatory demyelination is benefi cial for reducing the accumulation of neurological disability. 6 We report the effi cacy of a weighted genetic risk score (wGRS) that combines weighted odds ratios from each of 16 loci that have been associated with MS 1 for prediction of a diagnosis of MS in three independent cohorts. We also assessed the added eff ect of the integration of clinical parameters and paraclinical measures of environmental exposure into the algorithm.
Methods Participants
Each of the four sample collections was collected for a diff erent purpose by diff erent investigators and is independent of the other collections. All participants were recruited for studies that were approved by the institutional review boards or ethics committee of the respective institutions, and all gave written informed consent for their DNA to be collected for genetic analysis. All participants with MS met the revised McDonald diagnostic criteria. 7 The alleles and odds ratios included in our model were selected from the replication arm of a meta-analysis 1 that comprised cohorts from the UK and USA (table 1) . In this study, we refer to this combined set of samples as the derivation samples: 2215 individuals with MS or clinically isolated syndrome (CIS) and 2189 healthy controls were included. The origin of the derivation samples has been described previously 1 and their characteristics are outlined in table 1. The MS susceptibility loci of the derivation samples are the only ones that have been previously published; 1 none of these individuals are included in any of the other three sample collections.
The fi rst validation set includes individuals recruited by Bayer Schering Pharma for therapeutic trials (table 2) . This sample collection is labelled as the therapeutic trial (TT) collection. One of these trialsBetaferon/Betaseron in newly emerging multiple sclerosis for initial treatment (BENEFIT) 8 -studied individuals with CIS. The other three trials-Betaferon Effi cacy Yielding Outcomes of a New Dose (BEYOND), 9 long-term follow-up of patients enrolled in the pivotal study of Betaseron in relapsing-remitting multiple sclerosis (LTF), 10 and the phase 2 study in patients with relapsing-remitting multiple sclerosis to evaluate the safety, tolerability, and eff ects as seen on monthly MRI of the CCR1 antagonist ZK 811752 (CCR1) 11 -studied individuals with MS. The TT cohort included 1340 patients. At the time of enrolment, 1132 of these individuals had a diagnosis of relapsing-remitting MS in accordance with the McDonald criteria and 208 had a diagnosis of CIS with MRI signs that were suggestive of demyelination. 95 of the patients with CIS developed MS during up to 5 years of observation. In these analyses, patients with MS were matched to 1109 controls from a genome scan for early myocardial infarction (the MIGEN study). 12 Because there is no known association between MS and early myocardial infarction, the controls in the MS analysis include healthy controls and individuals with early myocardial infarction from the MIGEN study who were not included in our recent meta-analysis of MS genome-wide association studies.
1 Therefore, these controls are not specifi cally matched to the TT cohort but are individuals of European ancestry who have a general prevalence of 0·001 for a diagnosis of MS.
The second validation set, from the Nurses' Health Study (NHS) and Nurses' Health Study II (NHS II) cohorts, contributed 143 individuals with MS and 281 matched controls; these have been described in earlier publications, 13 and their characteristics are described in table 2.
To assess the role of our wGRS in the conversion of individuals with CIS to a diagnosis of MS, we analysed a subset of individuals from the TT collection who were in the placebo arm of the BENEFIT study. 8 All participants were followed up for 24 months, and a diagnosis of clinically defi nite MS was made on the basis of established criteria. 8 We also analysed the data from a cohort of patients with CIS from the Observational Study of Early Interferon beta-1a Treatment in High Risk Subjects after CIS (SET) who were recruited in Prague, Czech Republic. Inclusion criteria for this study were a diagnosis of CIS, at least two hyperintense lesions seen on MRI, and oligoclonal bands in the CSF. These patients were enrolled in the SET study within 4 months of the fi rst symptoms. All patients were treated with interferon beta-1a and were followed up for 24 months, and all clinical events were recorded.
Procedures and statistical analyses
We included 16 single nucleotide polymorphisms (SNPs) in our wGRS algorithm. These SNPs were chosen at the end of the replication stage of the meta-analysis:
1 nine of the SNPs are located in validated MS susceptibility loci that were reported to exceed genome-wide signifi cance (p<5×10 -⁸) in the meta-analysis or in previous publications; and seven of the SNPs were strongly suggestive of association with MS in the meta-analysis (p<10 -⁴ in the fi nal joint analysis). Four of these SNPs were previously validated as susceptibility markers for other infl ammatory diseases.
1 Since then, these seven SNPs have been validated in other sample collections (P De Jager, unpublished data).
For the derivation samples, genotype data were acquired as part of our previous study, by use of the Sequenom MASSarray platform and its iPLEX format. 1 The same platform was used to acquire data on the participants in the NHS/NHS II and SET cohorts. Genotypes for the TT and MIGEN individuals were collected using Aff ymetrix Genechip 6.0 arrays.
We developed a wGRS that used the allelic odds ratios from our previous study 1 to ascertain the strength of the genetic association with each allele. We calculated a wGRS that included two MHC alleles and 14 non-MHC risk alleles. The weighted score is preferred over a simple-count genetic score risk that is equal to the sum of the number of risk alleles carried because the HLA DRB1*1501 allele has a substantially higher odds ratio for MS susceptibility than do the recently discovered SNPs ( SNPs are listed by chromosome. All ORs used in the algorithm are referenced to the risk allele of each SNP, which can be the minor or major allele. *SNPs have their major allele as the risk allele; as the OR in the initial report 1 is referenced to the minor allele, here we convert the original OR for these SNPs to refl ect the use of the major allele as the reference allele using 1/(OR of the minor allele). SNP=single nucleotide polymorphism. OR=odds ratio. where i is the SNP, w i is the weight for SNP i, and X i is the number of risk alleles (0, 1, or 2). Table 3 shows the weights for each SNP, where the weight is the natural log of the odds ratio for each allele. By use of the odds ratio from the replication stage of our analysis, we have minimised the eff ect of infl ation of the odds ratios that would be expected in a risk-allele discovery study. In addition, the standard errors of those estimates were all small, in view of the large sample sizes from these analyses. 1 We repeated our wGRS calculations to take into account the variance of the odds ratio estimates, but this did not aff ect our results.
To assess the eff ect of the HLA DRB1*1501 allele, we also calculated a wGRS without HLA (ie, no DRB1*1501) that included only the common variants that have modest eff ects on MS susceptibility. After the individuals with more than 10% of their genotype data missing were removed, any individual with information missing for a particular SNP was assigned a value of twice the risk allele frequency for that SNP, which is the expected value for that SNP in the population. Because there is currently no evidence of epistasis among these susceptibility loci, we have not added terms for interaction between the loci in our algorithm. In each set of samples, the distribution of the wGRS was plotted separately for individuals with MS and controls and compared with two independent sample t tests. All analyses were done using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Because a continuous score is diffi cult to interpret on an individual level when a physician needs to explain the results of the wGRS to a patient, we partitioned participants into diff erent categories of risk. These categories were created from the means and SD from the control samples that were specifi c to each population. The seven categories were defi ned as 0·25, 0·75, and 1·25 SD from the mean; the extreme categories were less than 1·25 or greater than 1·25 SD from the mean. The division of our score into seven categories provided a robust distribution that enabled us to break down the groups with the highest and lowest risk but still ensure that there were statistically suffi cient numbers of individuals with MS and controls in the extreme categories. To avoid exaggerating the odds ratio associated with a specifi ed subject category, we used the largest subset of participants that contained the mean of the healthy control population (category 4) as the reference category. These individuals can be regarded as those with the mean risk of the assessed population. Within each dataset, we fi tted a single logistic regression model (controlling for sex in the derivation and TT samples and for smoking status and titres of anti-EBV nuclear antigen 1 [EBNA1] in the NHS/NHSII 
sample) with dummy variables for wGRS groups, to study the association of wGRS with MS; we compared each category of wGRS with the reference median category 4 (table 4 ). An ordinal wGRS variable based on our categories was used to calculate p values for trends. We also calculated the odds ratio of MS comparing the individuals in the highest wGRS category with those in the lowest wGRS category.
To ascertain how well our wGRS predictors discriminate between individuals with demyelinating disease and controls, we generated receiver operating characteristic (ROC) curves by plotting the sensitivity of the continuous wGRS score against 1-specifi city and calculating the area under the ROC curves (C statistic) for each population. The C statistic is a measure of the ability of the model to discriminate between individuals with MS and controls for every possible pair of case and control. To assess the degree to which the HLA DRB1*1501 allele contributes to the wGRS, we plotted ROC curves for a wGRS that excluded HLA DRB1*1501 and for the wGRS that included HLA DRB1*1501. The C statistic of each curve was compared by use of a non-parametric approach, as described by De Long and colleagues.
14 When available, additional susceptibility factors were considered: in the TT cohort, sex was added to the model; and in the NHS cohorts, smoking and EBV titres were added to the model.
The patients with CIS in the TT cohort were from the placebo arm of the BENEFIT study and were assessed for 24 months for evidence of activity of clinical disease. The last visit in the study was scheduled for between day 692 and day 741. Therefore, the time to a diagnosis of MS is defi ned as a right-censored variable: the time to MS is censored if the patient was lost to follow-up at any time up to day 692, or at day 692 if clinically defi nite MS had not been diagnosed before then. The association between the wGRS and the time to diagnosis of MS was assessed with the proportional hazards model. Non-linearity of the regressor wGRS was tested by including a quadratic term for wGRS, and the proportional hazards assumption was tested by including a time-dependent covariate that was the interaction between wGRS and log(time). The model was also extended to include the variables age and sex. The analysis was repeated for the 182 participants in the SET study who were followed up for up to 1271 days.
Role of the funding source
The study sponsor had no role in the study design, collection, analysis or interpretation of the data, or writing of the report. The corresponding author had full access to all the data in the study and fi nal responsibility for the decision to submit for publication.
Results
The wGRS was based on the odds ratios reported for the MS susceptibility loci, which were calculated from the data from the replication arm of our recent meta-analysis. We expected our current wGRS model to be over-fi tted when it was applied to these cohorts as we used these data when we developed the model. However, empirically, the eff ect might be slight. Figure 1 shows the distribution of wGRS in the derivation and validation samples. Both sets of curves show a clear separation between the distribution of the individuals with MS and that of the healthy controls.
In the derivation sample, the mean (SD) of the wGRS was 3·5 (0·7) for individuals with MS and 3·0 (0·6) for the controls (p<0·0001); the mean for the TT validation sample was 3·4 (0·7) for individuals with MS versus 3·1 (0·7) for controls (p<0·0001); and the mean for the smaller NHS/NHS II dataset was 3·4 (0·8) for individuals with MS versus 3·0 (0·7) for controls (p<0·0001). Another way to show the diff erence in the distribution of wGRS between individuals with MS and controls is to partition the participants. We did this by defi ning risk categories, starting at the mean wGRS in the controls of a sample collection and grouping individuals who are within 0·25 SD of the mean as category 4. Individuals in category 4 approximate to the group of participants with the mean population risk of MS (fi gure 2). Six subsequent categories (1-3 and 5-7) are defi ned by the increasing intervals of wGRS. In the set of combined derivation samples, category 7 individuals (ie, those with the largest wGRS) had 3·6 times (95% CI 2·9-4·3) increased odds of developing MS compared with those in category 4, the mean population risk (table 4) . When controlling for sex, in view of the greater proportion of women with MS, the odds for category 7 versus category 4 was unchanged (3·7, 2·8-4·3). When category 7 was compared with category 1, which contains the individuals with the lowest risk of MS, there was a 10·1 (6·9-14·7) times increase in the odds of developing MS. In the validation TT sample, individuals in category 7 (ie, those with the largest wGRS) had a mean increase in odds of developing MS of 2·4 (1·8-3·2) compared with individuals in category 4 (fi gure 2). When controlling for sex, the odds were 2·3 (1·7-3·0) for category 7 compared with category 4. The risk increased to 4·5 (3·0-7·0) when category 7 was compared with category 1. The application of the wGRS method in the NHS/NHS II collection gave similar results: the odds of developing MS in individuals in category 7 was 2·2 (1·1-4·5) compared with individuals in category 4 (fi gure 2). Because all the individuals in the NHS/NHS II are women, we were unable to adjust for sex in this sample. Table 5 shows the C statistics we calculated to estimate how well our algorithm could discriminate between individuals with MS and controls. The wGRS showed the best discrimination between individuals with MS and controls when assessed in our combined derivation sample, with a C statistic of 0·697. This discrimination was signifi cantly enhanced (p<0·0001) if we included sex in our model because sex is a known risk factor for MS (C statistic=0·741). Our algorithm performed nearly as well in both of our validation sample collections (fi gure 3); the C statistic was similar in the two sample collections (0·635 for TT [0·721 when controlling for sex], p<0·0001; and 0·635 for NHS/NHS II, p=0·02). This level of predictability remains modest, but our algorithm clearly and consistently performs better than chance, even though it is based on just 16 MS susceptibility loci.
Much of the predictive power comes from the HLA DRB1*1501 allele, which is common in individuals of European ancestry and has a large eff ect on susceptibility to MS (odds ratio=2·8).
1 Nonetheless, as shown in table 5, the other alleles also contribute to the wGRS (C statistic: 0·611 in the combined derivation sample, 0·558 in the TT sample, and 0·566 in the NHS/NHS II sample) when the HLA DRB1*1501 allele is excluded. A second MHC susceptibility allele, HLA B*44, has a slighter eff ect on susceptibility than does DRB1*1501; however, even after we excluded HLA B*44 from our model, non-MHC alleles made a consistent contribution to the wGRS (derivation sample=0·600; TT sample=0·562; and NHS/NHSII=0·546). The contribution of the non-MHC loci to the wGRS should increase as more susceptibility loci are identifi ed.
We, and others, have shown that the eff ects of anti-EBV antibody titres (specifi cally anti-EBNA1 titres) on susceptibility to MS 8, 15 is distinct from the eff ects contributed by the HLA DRB1*1501 allele. We therefore expanded our wGRS to include this environmental susceptibility factor and smoking, which is independently associated with the risk of MS. 4 These additional variables enhanced the predictive power of the wGRS: the C statistic for a model that included the wGRS and the environmental risk factors was 0·683 (0·635 for a model that included just the wGRS) in the NHS/NHS II cohort, for which these variables are available.
The cohort of 182 patients with CIS from the SET study had the same distribution of wGRS as did individuals in the NHS/NHS II samples that all have a diagnosis of MS (p=0·98), suggesting there is little diff erence between genetic susceptibility to CIS or MS. We also assessed the possibility that the genetic factors associated with susceptibility (ie, with the onset of infl ammatory demyelination) have a role in disease course, by assessing whether the wGRS of individuals with CIS is associated with the time from the onset of symptoms to the time of a second demyelinating event, and hence a diagnosis of MS, in the Czech SET and TT cohorts. In the subset of patients with CIS in the placebo group of the TT collection, the estimated hazard ratio from the univariate proportional hazards model for wGRS was 1·00 (95% CI 0·71-1·41; p=0·99). The estimated hazard ratio did not change substantially after age and sex were included. There was no evidence for a non-linear association of wGRS with the log hazard ratio (p=0·74) or for a deviation from the proportional hazards assumption (p=0·087). The individuals in the Czech SET study had a similar fi nding: the univariate proportional hazards model for wGRS was 0·82 (0·54-1·26; p=0·36).
Discussion
Genome-wide association scan methods have been successful in discovering susceptibility loci for MS and other infl ammatory diseases, and the repertoire of susceptibility alleles will expand further when ongoing whole-genome scans are completed. For the most part, the susceptibility alleles that have been identifi ed so far fi t the profi le targeted by genome-wide association studies: we have discovered alleles with a frequency more than 0·05 and small odds ratios (1·1-1·3). Whether the identifi cation of these allelic variants is clinically meaningful must be ascertained. For each patient, the identifi cation of a single polymorphism that is common in the general population but has a small eff ect is not informative. However, because there are many MS susceptibility loci with common alleles, the aggregate risk is informative when estimating the probability that an individual has MS. Indeed, this fi rst iteration of our algorithm, which used just 16 loci, is robust and provides consistent predictive ability in two collections of individuals that had not been assessed in previous gene discovery studies. Our algorithm is fl exible because additional loci, whether they contain common or rare alleles, can easily be added to enhance its predictive ability. Our algorithm also includes both risk and protective loci by the use of biallelic SNP markers. Currently, the algorithm does not include terms for interaction among the loci because there has been no validated evidence of such interactions in the genetic data examined to date. Such interactions might be robustly shown over time, and the algorithm can be easily modifi ed to take such observations into account. The MHC has a dominant role in the current algorithm (table 5; fi gure 3) owing to the large eff ect size and high frequency of the HLA DRB1*1501 allele, but the other alleles can also predict a diagnosis of MS. Because the distribution of wGRS cannot be distinguished between individuals with MS or those with CIS who are at high risk of MS on the basis of MRI criteria (fi gure 1), the model therefore seems to be applicable not only to MS, but also to CIS. Nonetheless, although the predictive ability of the algorithm is robust, it is not ready for clinical deployment. The C statistics from our wGRS analyses show that much of the variance in MS susceptibility is not explained by the current models. Indeed, even with a larger complement of the potential 50 or more MS susceptibility loci, the algorithm might not be suffi ciently eff ective. Our investigation of the NHS/NHS II sample collection, which generates a small dataset, suggests that the best strategy will probably require the inclusion of non-genetic susceptibility factors to enhance the algorithm and make it useful in a clinical setting: the environmental risk factors assessed in this study seem to provide information that is non-redundant relative to the genetic data (fi gure 3). Thus, future prospective studies of the wGRS should include detailed environmental and immuno logical characterisations. Overall, our best C statistic for the model that includes sex is currently 0·721, which is close to the Framingham Risk Score for coronary heart disease (C statistic about 0·8), which is regarded as clinically useful. 16 Thus, future iterations of the algorithm might reach a level of prediction of MS susceptibility that is also useful in a clinical setting.
Our initial assessment of the wGRS for predicting relapse after an initial episode of infl ammatory demyelination suggests that the current version of the algorithm is not useful for this crucial question. The mechanisms involved in the recurrence of infl ammatory demyelination might therefore be diff erent from the mechanisms involved at the onset of demyelinating disease. However, although we have assessed two diff erent populations of individuals with CIS (one that was treated with interferon beta-1a and one that was untreated) that show similar results, both sample collections are small and have a short follow-up and a low rate of clinical events. Our results should therefore be interpreted with caution, and further investigations are needed that include other parameters that relate to disease course and disease activity.
How could the wGRS be used in a clinical setting? The inciting event for MS is not observed, remains unknown, and is likely to occur months or years before the onset of clinical symptoms, which are often preceded by asymptomatic CNS lesions. 14 The partitioning of individuals into seven categories might be a way to help the communication of the results of the wGRS to physicians and ultimately to patients. The identifi cation of individuals with a high genetic risk for MS (category 7) might therefore open new avenues of investigation and treatment that could prevent the onset of the disease, rather than modifying its course once it is already symptomatic. In particular, a version of the wGRS might eventually be helpful in stratifying the risk for individuals who are already known to be at high risk, such as those with a fi rst-degree relative with MS, who have a 2-5% risk of MS (20-50 times greater than that of the general population of European ancestry). 5 Because vitamin D defi ciency has been associated with MS susceptibility, benign interventions, such as vitamin D screening and supplementation, could be done in individuals in high-risk categories. Furthermore, owing to the benefi t of early treatment for minimising later disability in individuals who have had one episode of demyelination, 8 and the observation that many individuals with asymptomatic T2 hyperintense lesions go on to have radiographic or clinical relapses, 17 there might be an argument for MRI screening of the fi rst-degree relatives of patients with MS who are in the top stratum of the wGRS distribution, to identify individuals during the clinically silent stage of the disease.
Overall, our data suggest that information obtained from MS susceptibility loci might provide useful information if used in the context of clinical algorithms that contain other information, such as environmental risk factors. We acknowledge that our estimate of genetic risk is still crude because it contains only a few of the susceptibility loci that are thought to exist. Further assessments of this method are therefore warranted, particularly when loci that are correlated with disease course in MS are discovered and a separate algorithm that can target progression can be designed.
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